They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
Subscribe To Our Newsletter & Stay Updated
